Applica

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09478299		
Filing Date		2000-01-05		
First Named Inventor John		L, Schenk		
Art Unit		1654		
Examiner Name M. M.		eller		
Attorney Docket Number		22091-701		

				U	.S.PATENTS			Remove
Examiner Initial*	Cite No				Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	4007087		1977-02-08	Encsson			
	2	7094527		2006-08-22	Seidel, et al			
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n informatio	n please click the	Add button.		Add
			U.S.P	ATENT AP	LICATION PUB	BLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		s,Columns,Lines where rant Passages or Relevan es Appear
	1	20050244805	A1	2005-11-03	Ludwig, et al.			
	2	20050282245		2005-12-22	Ludwig et al.			
	3	20050214733	A1	2005-09-29	Graham et a	. 7		
If you wisl	h to a	l dd additional U.S. Publ	ished Ap	l plication cita	tion information	please click the Ade	d butto	n. Add
				FOREIGN F	ATENT DOCUM	MENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		d Publication de4 Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09478299	
Filing Date		2000-01-05	
First Named Inventor John		L Schenk	
Art Unit		1654	
Examiner Name M. M.		eller	
Attorney Docket Number		22091-701	

	1	93/17322	wo	A1	1993-09-02	Univ. of Hertfordshire GB			
	2	2006012597	wo	A2	2006-02-02	Monsanto Technology LLC			
	3	1471019	UK		1977-04-21	United Aircraft Corp			
If you wisl	h to ac	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	Add		
			NON-PATE	IT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No								
	1	US Nonprovisional Application Number 10/266,562, Fied 10/07/2002, Office Action Dated 08/23/2006							
	2	Rath, D. et al., In Vitro Production of Sexed Embryos for Gender Preselection: High-speed sorting of X-Chromosome- Bearing Sperm to Produce Pigs After Embryo Transfer, J. Anim. Sci. 1999, 77:3346-3352							
	3	Auchtung, T.L., et al., Effects of Photoperiod During the Dry Period on Prolactin, Prolactin. Receptor, and Milk Production of Dairy Cows, Journal of Dairy Sci. 88. 121-127, American Dairy Sci. Assoc., 2005							
	4	Bailey, Tom and Currin, John Milk Production Evaluation in First Lactation Heifers, 1999 Virginia Cooperation Extension/Darry Science Publication 404-285							
	5	Belloin, J.C., Milk and Dairy products production and processing costs Food and Agriculture Organization of United Nations Rome 1988 FAO, web page where found: www.fao.org/docrep1003/bf6931eX6931E00.htm							
	6	Kurne, Shin-chi, Dept of Animal Nutrition National Institute of Animal Industry Tsukuba 305, Japan THE DAIRY INDUSTRY SIN ASIA B. JAPAN, www.agnet.org/library/sintcle/eb334b.html							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09478299
Filing Date		2000-01-05
First Named Inventor John		L Schenk
Art Unit		1654
Examiner Name M. M.		eller
Attorney Docket Number		22091-701

	7	Crother E.: Huffman S. McGivenny X. and Schenk, J. 347 Artificial Insemination of Lactating Holstein Cows with sexed sperm Abstract. CSORP Publishing - Reproduction, Fertility and Development www.publish.csro.au/nd/44/ [p					
	8	Lopez, H., Caraviello, D. Z., Satler, L. D., Fricke, P. M. and Willbank, M. C., Relationship Between Level of Milk Production and Multiple Ovulation in Lactating Dary Cows Journal of Dairy Sci. 88 2783-2793, American Dairy Science Association, 2005.					
	9	Managing the Dairy Cow During the Dry Period, Dairy Cattle Production 341-450A, Macdonaid Campus of McGill University/Faculty of Agricultural & Environmental Sciences/Department of Animal Science					
	10	Milk Production and Biosynthesis University of Guelph/Dairy Science and Technology www.foodsct.uoguelph.ca/ dairyedu/biosyntheses.html					
	MILK PRODUCTION Released 7-18-2006, by the National Agricultural Statistics Service (NASS), Agri. Statis. Board, US Dept of Agri.						
	12	De Viries, A. Economic Value of Pregnancy in Dairy Cattle Journal of Dairy Sci. 89.3876-3885/American Dairy Sci. [
If you wish	h to a	dd additional non-patent literature document citation information please click the Add button Add					
		EXAMINER SIGNATURE					
Examiner	Signa	ature Date Considered					
		ititial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a conformance and not considered. Include copy of this form with next communication to applicant.					

1 See KinG Codes of USPTO Patient Documents at year LISPTO, GDU, or MRCP 901.64. ² Extent office that issued the document, by the low-liter code (NIPO Standard ST3, ³ For Juapanes patient counsent), the indication of the year of the Proprior many seconds the estimation of counsely and counsely and counsely and the patient of the Proprior many seconds are set on under of the patient counsely. ⁴ Kind of counsely by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ³ Applicant is to place a check mark here if English Banquage Intendation is attacked.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09478299		
Filing Date		2000-01-05		
First Named Inventor John		L Schenk		
Art Unit		1654		
Examiner Name	M. M	eller		
Attorney Docket Number		22091-701		

48 665

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any inclinication designated in 37 CPR1 156(c) more than three months prior to the filing of the information disclosure any inclinication.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Nicole A. Ressue

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/Nicole A. Ressue/	Date (YYYY-MM-DD)	2006-10-02

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 3 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of C

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.